171 related articles for article (PubMed ID: 21051971)
1. Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies.
Greer HO; Frederick PJ; Falls NM; Tapley EB; Samples KL; Kimball KJ; Kendrick JE; Conner MG; Novak L; Straughn JM
Int J Gynecol Cancer; 2010 Nov; 20(8):1321-5. PubMed ID: 21051971
[TBL] [Abstract][Full Text] [Related]
2. Tumor board in gynecologic oncology.
Santoso JT; Schwertner B; Coleman RL; Hannigan EV
Int J Gynecol Cancer; 2004; 14(2):206-9. PubMed ID: 15086716
[TBL] [Abstract][Full Text] [Related]
3. An analysis of the impact of pathology review in gynecologic cancer.
Chafe S; Honore L; Pearcey R; Capstick V
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1433-8. PubMed ID: 11121644
[TBL] [Abstract][Full Text] [Related]
4. Tumor board: more than treatment planning--a 1-year prospective survey.
Gatcliffe TA; Coleman RL
J Cancer Educ; 2008; 23(4):235-7. PubMed ID: 19058072
[TBL] [Abstract][Full Text] [Related]
5. Review at a multidisciplinary tumor board impacts critical management decisions of pediatric patients with cancer.
Thenappan A; Halaweish I; Mody RJ; Smith EA; Geiger JD; Ehrlich PF; Jasty Rao R; Hutchinson R; Yanik G; Rabah RM; Heider A; Stoll T; Newman EA
Pediatr Blood Cancer; 2017 Feb; 64(2):254-258. PubMed ID: 27578484
[TBL] [Abstract][Full Text] [Related]
6. The multidisciplinary tumor conference in gynecologic oncology--does it alter management?
Cohen P; Tan AL; Penman A
Int J Gynecol Cancer; 2009 Dec; 19(9):1470-2. PubMed ID: 19955920
[TBL] [Abstract][Full Text] [Related]
7. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board.
Newman EA; Guest AB; Helvie MA; Roubidoux MA; Chang AE; Kleer CG; Diehl KM; Cimmino VM; Pierce L; Hayes D; Newman LA; Sabel MS
Cancer; 2006 Nov; 107(10):2346-51. PubMed ID: 16998942
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study.
Lee B; Kim K; Choi JY; Suh DH; No JH; Lee HY; Eom KY; Kim H; Hwang SI; Lee HJ; Kim YB
Medicine (Baltimore); 2017 Dec; 96(48):e8089. PubMed ID: 29310324
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary Lung Cancer Tumor Board Connecting Eight General Hospitals in Japan via a High-Security Communication Line.
Takeda T; Takeda S; Uryu K; Ichihashi Y; Harada H; Iwase A; Tamura Y; Hibino M; Horiuchi S; Kani H
JCO Clin Cancer Inform; 2019 Mar; 3():1-7. PubMed ID: 30860865
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board.
Wheless SA; McKinney KA; Zanation AM
Otolaryngol Head Neck Surg; 2010 Nov; 143(5):650-4. PubMed ID: 20974334
[TBL] [Abstract][Full Text] [Related]
11. Value of Specialist Pathology Review in a Single Statewide Gynecologic Cancer Service.
Melon J; Leung Y; Salfinger SG; Tan J; Mohan G; Cohen PA
Int J Gynecol Cancer; 2017 Jan; 27(1):171-176. PubMed ID: 28002209
[TBL] [Abstract][Full Text] [Related]
12. Gynecologic oncology tumor board: the central role of the radiologist.
Recht HS; Shampain KL; Flory MN; Nougaret S; Barber EL; Jha P; Maturen KE; Sadowski EA; Shinagare AB; Venkatesan AM; Horowitz JM
Abdom Radiol (NY); 2023 Oct; 48(10):3265-3279. PubMed ID: 37386301
[TBL] [Abstract][Full Text] [Related]
13. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
[TBL] [Abstract][Full Text] [Related]
14. Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program.
Kuroki L; Stuckey A; Hirway P; Raker CA; Bandera CA; DiSilvestro PA; Granai CO; Legare RD; Sakr BJ; Dizon DS
Gynecol Oncol; 2010 Mar; 116(3):295-300. PubMed ID: 20042225
[TBL] [Abstract][Full Text] [Related]
15. Initiation of a formalized precision medicine program in gynecologic oncology.
Gunderson CC; Rowland MR; Wright DL; Andrade KL; Mannel RS; McMeekin DS; Moore KN
Gynecol Oncol; 2016 Apr; 141(1):24-8. PubMed ID: 27016225
[TBL] [Abstract][Full Text] [Related]
16. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.
Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Burges A; Trillsch F; Mahner S; Harbeck N; Wuerstlein R
Arch Gynecol Obstet; 2021 May; 303(5):1331-1345. PubMed ID: 33277683
[TBL] [Abstract][Full Text] [Related]
17. Endocrine Tumor Board: Ten Years' Experience of a Multidisciplinary Clinical Working Conference.
Savitz A; Fong B; Hochberg A; Rumore G; Chen C; Yun J; Sadur C
Perm J; 2020; 24():. PubMed ID: 32663125
[TBL] [Abstract][Full Text] [Related]
18. Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.
Charo LM; Eskander RN; Sicklick J; Kim KH; Lim HJ; Okamura R; Lee S; Subramanian R; Schwab R; Shatsky R; Plaxe S; Kato S; Kurzrock R
JCO Precis Oncol; 2022 Jan; 6():e2000508. PubMed ID: 35005995
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Gynaecological Tumour Board Rounds on Patient Care.
Halliday DA; Warfa K; Duggan MA; Nation J; Chu P; Nelson G; Glaze S; Mateshaytis J; Ghatage P
J Obstet Gynaecol Can; 2019 Feb; 41(2):180-184.e1. PubMed ID: 30393059
[TBL] [Abstract][Full Text] [Related]
20. The utilization of palliative care in gynecologic oncology patients near the end of life.
Fauci J; Schneider K; Walters C; Boone J; Whitworth J; Killian E; Straughn JM
Gynecol Oncol; 2012 Oct; 127(1):175-9. PubMed ID: 22735789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
